Long-Term Capital: Finding a Patient PE Partner for Your Vision
Long-term or patient capital comes from evergreen funds with no fixed expiration date, unlike traditional private equity funds that must buy and sell companies within roughly a decade. Patient capital frees a firm to act as a true long-term owner-operator, aligning investor interests with the sustained health of your business rather than a forced, schedule-driven exit.
The Traditional Private Equity Model: A Fixed Horizon
The traditional private equity model operates on a fixed-term fund structure, typically a 10-year lifespan. This legally binding vehicle mandates that the general partner invest capital from its limited partners and liquidate those investments within a predetermined timeframe.
The structure creates a rigid timeline: an investment period for new deals, a phase of operational improvement and growth, and an exit period to realize returns. This pressures the firm to find a buyer or pursue an IPO on a strict schedule regardless of market conditions, so decisions may prioritize a quick sale over patient, multi-decade value creation.
Patient Capital: An Evergreen Alternative
In contrast, patient capital vehicles, often called evergreen funds, are structured without a fixed expiration date. They are typically financed by entities with a perpetual investment horizon, such as large family offices, sovereign wealth funds, and publicly traded holding companies.
This model liberates the firm from the pressure of a forced exit, empowering it to function as a true long-term owner-operator. Without a looming deadline, management can build sustainable value through patient investments in R&D, major infrastructure projects, and strategic acquisitions, an approach famously exemplified by Berkshire Hathaway.
- Large family offices
- Sovereign wealth funds
- Publicly traded holding companies
Investment Horizon and Strategic Focus
The core difference lies in the investment horizon and resulting strategic focus. The 10-year fund is a transaction-oriented model where success is measured by achieving a high return within a constrained timeframe, with decisions geared toward enhancing the company's appeal for a near-term sale.
The patient capital model is value-creation-oriented, measured not solely by an exit but by compounding returns and the sustained health of the business. This difference dictates every decision, making patient capital more suitable for founders who prioritize legacy and sustained growth over a quick liquidity event.
The IRR vs. MOIC Dilemma
Traditional funds favor IRR, a time-sensitive, annualized metric that answers how fast money was made. Quick exits can yield high IRRs even when absolute profit is lower, which supports fundraising. Long-term strategies favor MOIC, a time-agnostic metric that answers how many times the money came back and captures the absolute magnitude of value creation through compounding.
A longer hold can double absolute profit even with a lower annualized return. LPs increasingly focus on MOIC and DPI for true cash-on-cash performance, recognizing that greater value is often created through long-term compounding that short holding periods curtail.
Fees and the Seller's Repurchase Option
Fee structures also differ. Traditional funds typically charge a 2% annual management fee on committed capital, while long-dated funds often feature lower fees, such as 1% to 1.5%, calculated on invested capital or NAV, aligning the GP's income with capital that is actively generating value.
A Seller's Repurchase Option is a contractual right allowing a founder to buy back their company under pre-negotiated conditions. Founders seek it to regain strategic control, mitigate undervaluation risk if the company was sold at a low point, or for personal and legacy reasons to protect the business they built.